Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2)

Anticancer Res. 1997 Jul-Aug;17(4A):2727-30.

Abstract

The pharmacokinetics of 5-fluorouracil (5-FUra) were investigated in 16 patients with metastatic colorectal cancer receiving high-dose folinic acid (LV 200 mg/m2) followed by 5-FUra bolus (400 mg/m2) and continuous infusion (600 mg/m2) on days 1 and 2. Quantitation of unchanged drug was assessed by a highly specific high-performance liquid chromatographic method. The concentrations of 5-FUra at the end of the loading dose averaged 30.7 +/- 13.2 micrograms/ml (i.e., 236 microM). The steady-state plasma concentration averaged 0.31 +/- 0.11 microgram/ml (i.e., 2.4 microM). 5-FUra plasma levels declined rapidly after the end of infusion with an apparent elimination half-life of 7.08 +/- 3.21 minutes. Clearance ranged from 776 to 3023 ml/min/m2. Large patient-to-patient variations in plasma 5-FUra concentrations were observed. No toxicity greater than WHO grade 2 was seen. One patient experienced grade 1 stomatitis and two others experienced grade 1 and 2 myelosuppression. One patient developed diarrhoea and another suffered asthenia. Nausea and vomiting were observed in 5 patients.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / pharmacokinetics*
  • Colorectal Neoplasms / drug therapy*
  • Female
  • Fluorouracil / adverse effects
  • Fluorouracil / blood
  • Fluorouracil / pharmacokinetics*
  • Humans
  • Leucovorin / administration & dosage*
  • Male
  • Middle Aged
  • Neoplasm Metastasis

Substances

  • Antimetabolites, Antineoplastic
  • Leucovorin
  • Fluorouracil